Screen for fungal diseases with BioConnections
COVID-19 infections present a significant risk of secondary infection, as seen in emerging reports of a link between COVID-19 and fungal co-infections such as aspergillosis.
Fungal co-infections are a severe threat to patients already weakened by COVID-19 infection. These fungal co-infections need to be identified rapidly for antifungal therapy to be successful.
Invasive fungal infections can be challenging to identify. Bringing fungal diagnostics in-house can lead to a significant reduction in result reporting turnaround time. BioConnections is introducing a range of products to UK clinical laboratories for the rapid detection of various biomarkers used to
screen for fungal diseases, and, when combined with the Merlin Micronaut antifungal susceptibility testing system, enables rapid targeted patient care.
More information on these new products is available from BioConnections through a virtual presentation.
www.bioconnections.net
Other News
Featured Supplier
Hamamatsu Photonics UK Limited is a world-leading manufacturer of optoelectronic components and systems. The Company's corporate philosophy stesses the advancement of photonics through extensve research and yields products that are regarded as state-of-the-art. Developments in digital imaging continue to be made by the Hamamatsu Systems Divison,...
Upcoming Events
Near Miss Events and Incident Investigation webinar
Online
19 May 2021
Lab Innovations 2021
NEC, Birmingham
3-4 November 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
